Randox Laboratories | GenomeWeb

Randox Laboratories

University of Geneva researchers in collaboration with the UK's Proteome Sciences have identified a protein marker that could help doctors better determine the time of stroke onset.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Proteome Sciences said today that it has signed a non-exclusive license with Randox Laboratories for use of its stroke protein biomarker portfolio.

Randox Laboratories has launched its Beta-Lactams Array.

Randox Laboratories this week launched its KRAS/BRAF/PIK3CA Array. The company said that clinicians can use the chip to select appropriate patients for colorectal cancer patients undergoing anti-EGFR therapy.

The offering is designed to complement the firm's menu of more focused screening tools.

The funding is for seven projects aimed at creating biomarkers to help guide patients to the most appropriate treatments and at creating drugs and companion diagnostics.

New Product Watch

Premium

Fluidigm's 192.24 Dynamic Array IFC, LC Sciences' V17 MicroRNA Microarrays, Arrayjet's Custom Microarray Services, Randox Laboratories' Quantiplasma Array

The Paris-based firms earlier this year announced a partnership to develop monoclonal antibody microarrays that combine BSI's antibodies with MBC's microarray platform.

New Product Watch

Premium

Gentel Biosciences' APiX Disease Profiling Kit, Randox Laboratories' Metabolic Syndrome Arrays

New Product Watch

Premium

Randox Laboratories, Ocimum Biosolutions, DNAVision, Illumina

Pages

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.